Evolocumab Biosimilar, Endotoxin 0.05 EU/mg
$900.00 – $1,800.00
Evolocumab Biosimilar, Endotoxin 0.05 EU/mg. The research grade evolocumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | C105P.05 |
|---|---|
| Product Name | Evolocumab Biosimilar, Endotoxin 0.05 EU/mg |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Proprotein Convertase Subtilisin/Kexin Type 9 |
| Summary | Recombinant fully human IgG2 Monoclonal Antibody. |
| Isotype | Human IgG2 lambda. |
| Source/Host | The anti-PCSK9 monoclonal antibody evolocumab biosimilar was produced in mammalian cells. |
| Specificity/Sensitivity | The monoclonal antibody evolocumab biosimilar specifically binds to the human PCSK9. |
| Form Of Antibody | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| Endotoxin | < 0.05 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The Evolocumab Biosimilar, Endotoxin 0.05 EU/mg is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | The research grade evolocumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card. |
Description
C105P.05: Evolocumab Biosimilar, Endotoxin 0.05 EU/mg
Recombinant fully human IgG2 Monoclonal Antibody.
Background
What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.
Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)
Please remember our product information: Evolocumab Biosimilar, Endotoxin 0.05 EU/mg: C105P.05 Syd Labs
Additional information
| Ship from Country | USA |
|---|---|
| Size | 20 mg, 5 mg |
